Young says CRISPR sickle-cell treatments cost millions and exclude his subtype

What was said

"it's so expensive it's 2 to3 $3 million per treatment they are only doing trial phases with the SS version and not the SC version despite my bones deteriorating, me having artificial hips, needing artificial shoulders, and my tailbone deteriorating too. I don't have that particular version."

Discussing sickle-cell disease and gene editing, Young says current CRISPR-based treatments are priced in the $2–3 million range and that trials focus on the SS form of sickle-cell, not his SC subtype. He links that exclusion to ongoing disability, including prior hip replacements and the prospect of further joint surgery.